India, March 6 -- Surmodics Inc. (SRDX) responded to the U.S. Federal Trade Commission's announcement that it will challenge the proposed acquisition by funds affiliated with GTCR LLC, stating that it respectfully disagrees with the FTC's decision and remains committed to completing the merger.
Surmodics said it remains confident in both its rationale for the Merger and the value it will bring to all stakeholders, including shareholders, customers and patients.
Surmodics noted that it has worked constructively with the FTC over the last several months to secure regulatory approval for the Merger and are disappointed by its decision to initiate litigation, as the Merger is pro-competitive. Surmodics intends to vigorously defend this case i...